RecruitingPhase 2NCT06850623

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer


Sponsor

EXACT Therapeutics AS

Enrollment

25 participants

Start Date

Jun 19, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether adding acoustic cluster therapy (ACT) — a technique that uses tiny gas bubbles and ultrasound waves to temporarily open up tumor blood vessels and improve drug delivery — to standard chemotherapy can improve outcomes for patients with locally advanced pancreatic cancer that cannot be surgically removed. **You may be eligible if...** - You have locally advanced pancreatic cancer (LAPC) or borderline resectable pancreatic cancer that is not suitable for primary curative surgery - Imaging and tissue samples are consistent with inoperable pancreatic cancer - Your doctors have determined you are suitable to receive mFOLFIRINOX chemotherapy (a standard combination chemotherapy regimen) **You may NOT be eligible if...** - You have already received any prior anti-cancer treatment for pancreatic cancer (surgery, chemotherapy, radiation, or investigational drugs) - Your cancer is resectable (surgically removable) upfront - Your general health is too poor to tolerate mFOLFIRINOX Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTAcoustic Cluster Therapy

Drug: PS101; Device: Ultrasound

DRUGModified FOLFIRINOX

Chemotherapy


Locations(10)

HonorHealth Research Institute

Scottsdale, Arizona, United States

Stanford Cancer Center Palo Alto

Stanford, California, United States

Beth Israel Deaconess Medical Center - Division of Hematology/Oncology

Boston, Massachusetts, United States

Henry Ford Centre

Detroit, Michigan, United States

Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Brown University Cancer Institute

Providence, Rhode Island, United States

CAMBRIDGE CANCER TRIALS CENTRE-Addenbrooke's Hospital

Cambridge, Cambridge, United Kingdom

Gary Weston Centre- Imperial College Healthcare- Du Cane Road

Hammersmith, London, United Kingdom

The Royal Marsden- Downs Road

Sutton, Surrey, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06850623


Related Trials